J&J builds case for HIV vaccine ahead of pivotal trial readoutJohnson & Johnson has moved a step closer to the goal of developing a vaccine that can help Share XJ&J builds case for HIV vaccine ahead of pivotal trial readouthttps://pharmaphorum.com/news/jj-builds-case-hiv-vaccine/
Sanofi/Regeneron’s Dupixent could be first biologic approved for nasal polypsTrials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic Share XSanofi/Regeneron’s Dupixent could be first biologic approved for nasal polypshttps://pharmaphorum.com/news/sanofi-regenerons-dupixent-could-be-first-biologic-approved-for-nasal-polyps/
Merck KGaA’s BTK drug reduces lesions in relapsing MS patientsGermany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) Share XMerck KGaA’s BTK drug reduces lesions in relapsing MS patientshttps://pharmaphorum.com/news/merck-kgaas-btk-drug-reduces-lesions-in-relapsing-ms-patients/
Ionis and Roche to develop RNAi AMD drug in $760m dealIonis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug Share XIonis and Roche to develop RNAi AMD drug in $760m dealhttps://pharmaphorum.com/news/ionis-and-roche-to-develop-rnai-amd-drug-in-760m-deal/
Number of UK clinical trials in decline since Brexit voteOngoing uncertainty and concern about Brexit has already cut the number of clinical trials carried out in the Share XNumber of UK clinical trials in decline since Brexit votehttps://pharmaphorum.com/news/number-of-uk-clinical-trials-in-decline-since-brexit-vote/
FDA gives go-ahead for CRISPR-based sickle cell disease trialDevelopment of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can Share XFDA gives go-ahead for CRISPR-based sickle cell disease trialhttps://pharmaphorum.com/news/fda-gives-go-ahead-for-crispr-based-sickle-cell-disease-trial/
New data sets up potential new gastro use for J&J’s StelaraJanssen’s Stelara has shown positive results in an ulcerative colitis (UC) trial, setting up a potential new indication Share XNew data sets up potential new gastro use for J&J’s Stelarahttps://pharmaphorum.com/news/new-data-sets-up-potential-new-gastro-use-for-jjs-stelara/
Novartis drug cuts serious complications in sickle cell diseaseNovartis’ developmental sickle cell disease drug crizanlizumab cut occurrences of a serious complication of the disease that can Share XNovartis drug cuts serious complications in sickle cell diseasehttps://pharmaphorum.com/news/novartis-drug-cuts-serious-complications-in-sickle-cell-disease/
UK biotech Orchard plans $172.5m US IPO to fund rare disease R&DUK biotech Orchard Therapeutics is planning a US IPO to expand use of its Strimvelis gene therapy, and Share XUK biotech Orchard plans $172.5m US IPO to fund rare disease R&Dhttps://pharmaphorum.com/news/uk-biotech-orchard-plans-172-5m-us-ipo-to-fund-rare-disease-rd/
